| Patient | Edward W. Brooke |
|---|---|
| Date of birth | 1942-10-26 |
| Identifiers | MRN HR-ML014-SYN; SSN (made up) 000-14-5063 |
| Document date | 2026-01-13 |
| Author | Howard Bellamy, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
First visit to establish shared care for breast cancer on adjuvant tamoxifen, fourteen weeks after bilateral mastectomy and right axillary dissection [S]
This fictional modern episode addresses the presenting concerns below. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
2 later historical claims are omitted because they describe events after the index age. See the teaching note.
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| September 2002 | Breast cancer of the right breast in a man, diagnosed after he noticed discomfort in the right breast; mammogram, sonogram, and needle biopsy; he had never had a chest examination by a doctor before | D (CLM-0003) |
| 2002 | Operation for breast cancer, reported as a double mastectomy, with removal of the lymph nodes on the right side, to which the cancer had spread | D (CLM-0004, CLM-0005) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Tamoxifen 20 mg oral tablet, one tablet by mouth once daily (adjuvant endocrine therapy, planned for at least five years) | One tablet once daily | Oral route | 2025-10-28 | active | S |
Positive for the concerns in the history of present illness. Alert, articulate, and courteous; prefers to keep his diagnosis private for now and asks direct questions about his treatment. Mood good; PHQ-9 minimal at the first visit. No other systems reported as affected in this synthetic episode. [S]
Alert and engaged. Independent in all activities and instrumental activities of daily living; full shoulder movement on both sides after surgery. Walks 30 to 40 minutes most days. [S]
Vital signs recorded on 2026-01-13; see the Vital Signs section. Mental status: Alert, articulate, and courteous; prefers to keep his diagnosis private for now and asks direct questions about his treatment; Mood good; PHQ-9 minimal at the first visit. The physical examination is limited to the findings relevant to this synthetic episode. [S]
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-01-13 | Body height | 183 | cm | S |
| 2026-01-13 | Body weight | 81.6 | kg | S |
| 2026-01-13 | Body mass index (BMI) [Ratio] | 24.4 | kg/m2 | S |
| 2026-01-13 | Systolic blood pressure | 134 | mm[Hg] | S |
| 2026-01-13 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-01-13 | Heart rate | 70 | /min | S |
| 2026-01-13 | Respiratory rate | 14 | /min | S |
| 2026-01-13 | Body temperature | 36.6 | Cel | S |
| 2026-01-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-01-13 | Hemoglobin [Mass/volume] in Blood | 13.8 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-01-13 | Leukocytes [#/volume] in Blood by Automated count | 6.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-01-13 | Platelets [#/volume] in Blood by Automated count | 214 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-01-13 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-01-13 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-01-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.04 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-01-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 71 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-01-13 | Calcium [Mass/volume] in Serum or Plasma | 9.3 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-01-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 | U/L | 7-55 U/L | Normal | S |
| 2026-01-13 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 23 | U/L | 8-48 U/L | Normal | S |
| 2026-01-13 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 76 | U/L | 40-129 U/L | Normal | S |
| 2026-01-13 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-01-13 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-01-13 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 24 | ng/mL | 30-100 ng/mL | Low | S |
| 2026-01-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Invasive ductal carcinoma of the right male breast, central (retroareolar) portion, stage IIA (pT1c pN1a M0), grade 2, ER positive, PR positive, HER2 negative; treated by bilateral mastectomy and right axillary lymph node dissection; on adjuvant tamoxifen; synthetic modern detail linked to his publicly disclosed breast cancer | active | confirmed | C50.121 | S — Synthetic tumor size, grade, receptor status, and stage; the diagnosis, the right side, the operation, and the spread to lymph nodes are from his public account (D). |
| Estrogen receptor-positive status of the breast cancer | active | confirmed | Z17.0 | S — Synthetic receptor result; his tumor biology was not made public. |
| Long-term use of tamoxifen, with safety monitoring (venous thromboembolism, mood, hot flashes, sexual side effects, adherence) and bone health review | active | confirmed | Z79.810 | S — Synthetic adjuvant therapy in the modern episode. |
| Absence of both breasts after bilateral mastectomy | active | confirmed | Z90.13 | S — The double mastectomy is reported publicly (D); the coding is synthetic. |